Perceptive Advisors LLC Uni Qure N.V. Transaction History

Perceptive Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$39.36 - $76.8 $11.1 Million - $21.6 Million	-281,820 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $2.64 Million - $4.11 Million	50,000 Added 21.57%	281,820 $22 Million
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $304,385 - $760,240	11,113 Added 5.04%	231,820 $13.8 Million
Q4 2018 Feb 14, 2019	SELL	$22.8 - $33.93 $17.1 Million - $25.5 Million	-752,124 Reduced 77.31%	220,707 $5.95 Million
Q3 2018 Nov 14, 2018	SELL	$29.75 - $43.08 $14 Million - $20.3 Million	-471,797 Reduced 32.66%	972,831 $35.4 Million
Q2 2018 Aug 14, 2018	BUY	$21.96 - $39.94 $1.1 Million - $2 Million	50,000 Added 3.59%	1,444,628 $54.6 Million
Q1 2018 May 15, 2018	BUY	$17.1 - $26.61 $5.93 Million - $9.23 Million	346,678 Added 33.08%	1,394,628 $32.8 Million
Q4 2017 Feb 14, 2018	BUY	$9.47 - $19.59 $74,159 - $153,409	7,831 Added 0.75%	1,047,950 $20.5 Million
Q3 2017 Nov 14, 2017	BUY	$7.7 - $9.6 $8.01 Million - $9.99 Million	1,040,119	1,040,119 $9.99 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.